Pancreatic Cancer News Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
In a pan-cancer analysis, patients with pancreatic acinar cell carcinoma had the highest prevalence of BRCA2 germline pathogenic variants.
Divarasib produced responses in patients with non-small cell lung cancer, colorectal cancer, and other solid tumors in a phase 1 trial.
Active smoking is associated with shorter overall survival in pancreatic cancer patients treated with neoadjuvant FOLFIRINOX, a study suggests.
Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests.
Black and Hispanic patients have a higher risk of death from second primary cancers than White and Asian/Pacific Islander patients, new data suggest.
SeekInCare, a blood-based multi-cancer detection test, can detect more than 20 cancer types with high specificity, according to researchers.
A study of patients in Texas suggests that surgery is underutilized for the treatment of resectable pancreatic ductal adenocarcinoma.
Hispanic patients have seen increases in cancer-specific mortality for certain cancers, including liver, pancreatic, and uterine cancer.
Research presented at ASCO 2023 highlights the latest developments in gastrointestinal cancer treatment.
ASCO has released recommendations outlining how to treat patients with gastrointestinal cancer while chemotherapy drugs are in short supply.
NALIRIFOX can improve survival vs gemcitabine plus nab-paclitaxel in patients with previously untreated, metastatic pancreatic ductal adenocarcinoma, a phase 3 trial suggests.
Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.
Survivors of childhood neuroblastoma have neurocognitive impairments that affect their ability to reach adult milestones, a study suggests.
Patients who are overweight or obese in early, middle, or late adulthood may have an increased risk of gastrointestinal cancers, a study suggests.
Higher levels of certain sex hormones are associated with an increased risk of some gastrointestinal cancers, a meta-analysis suggests.
Nonalcoholic fatty liver disease is associated with an increased risk of young-onset digestive tract cancers, a study suggests.
Adagrasib produced responses in a phase 1/2 trial of patients with heavily pretreated, KRAS G12C-mutated solid tumors.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Load More